GLP-1 receptor agonists improve glycemic control and weight while reducing cardiovascular events, with tolerability limited by gastrointestinal adverse effects requiring gradual dose escalation.
Injected medications that treat diabetes and obesity increase the risk of a rare but serious side effect: stomach paralysis, according to new data on the real-world use of the drugs. At least three ...
As the early signs of GLP-1-driven disruption emerge in the food sector, more manufacturers are exploring weight management-friendly innovation. The shift isn’t seismic yet, but momentum is building.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results